Is Capricor Therapeutics, Inc. (CAPR) a Buy, Sell, or Hold?
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$20.68 USD
$0.07 (0.34%)
- Volume
- 0
- Average Volume
- 1.2M
- Market Capitalization
- $945.43M
- P/E Ratio
- -8.91
- Dividend Yield
- 0.00%
- Price Target
- $50.00
- Year High
- $40.37
- Year Low
- $4.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.42
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Linda Marbán |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CAPR |
| CUSIP | 14070B309 |
| CIK | 0001133869 |
| Web | https://www.capricor.com |
| Phone | 310 358 3200 |
| Currency | USD |
| Employees | 231 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.08 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.42 |
| Quick Ratio | 8.42 |
| Cash Ratio | 3.13 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.98 |
| Price / Cash Flow | -8.30 |
| Price / Book | 4.26 |
Price Target and Rating
| Average Stock Price Forecast | $50.00 |
| High Stock Price Forecast | $62.00 |
| Low Stock Price Forecast | $38.00 |
| Forecast Upside/Downside | -58.64% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.26 |
| Trailing P/E Ratio | -8.91 |
| PEG Ratio | 0.20 |
| P/E Growth | 0.20 |
| Net Income | $-105.04M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -59.27% |
| Return on Assets | -35.12% |
Financials Score
| AltmanZ Score | 10.03 |
| Piotroski Score | 3.00 |
| Working Capital | 249.45M |
| Total Assets | 326.28M |
| Ebit | -111.55M |
| Market Cap | 927.15M |
| Total Liabilities | 47.58M |
Poll Results
About Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA. ...
What's Going On With Capricor Therapeutics Stock On Friday?
2026-06-26 14:06:40
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.
2026-06-26 10:02:00
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–
2026-06-26 09:05:00
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company's HOPE-3 Phase 3 trial.
Caprock Announces Closing of Private Placement
2026-06-19 17:47:00
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement offering of 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of $600,000 (the "Offering"). The Offering was initially announced in the Company's press release dated June 12, 2026.
2026-06-17 16:32:51
Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $19,136.00 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 20,602,166 common shares and 4,633,333 common share purchase warrants of the Issuer, representing approximately 19.35% of Caprock's issued and outstanding common shares assuming exercise of the common share purchase warrants held by the Acquiror.
Caprock Announces Proposed Private Placement
2026-06-12 18:02:00
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of up to $600,000 (the "Offering"). The Company may, in its discretion and subject to the approval of the Canadian Securities Exchange (the "CSE"), increase the size of the Offering.
2026-06-12 17:40:00
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from the Final 3 Deep Drill Holes: DES-26-184W1: Intersected 8.32 g/t Au over 2.6m and 6.43 g/t Au over 1.8m.
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
2026-06-11 09:04:06
Capricor Therapeutics NASDAQ: CAPR executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.
Frequently Asked Questions
-
What is the current Capricor Therapeutics, Inc. (CAPR) stock price?
-
Capricor Therapeutics, Inc.(NASDAQ:CAPR) stock price is $20.68 in the last trading session. During the trading session, CAPR stock reached the peak price of $40.37 while $4.3 was the lowest point it dropped to. The percentage change in CAPR stock occurred in the recent session was 0.34% while the dollar amount for the price change in CAPR stock was $0.07.
-
CAPR's industry and sector of operation?
-
The NASDAQ listed CAPR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CAPR?
-
Frank Isaac Litvack FACC | Executive Chairman of the Board
Michael Maurer | Chief Commercial Officer
Kristi A. H. Elliott | Chief Operating & Science Officer
Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer
Minghao Sun | Senior Vice President of Quality Control, Research & Product Development -
How many employees does CAPR have?
-
Number of CAPR employees currently stands at 231. CAPR operates from 10865 Road to the Cure, San Diego, CA 92121, US.
-
Link for CAPR official website?
-
Official Website of CAPR is: https://www.capricor.com
-
How do I contact CAPR?
-
CAPR could be contacted at phone #310 358 3200 and can also be accessed through its website. CAPR operates from 10865 Road to the Cure, San Diego, CA 92121, US.
-
How many shares of CAPR are traded daily?
-
The average number of CAPR shares traded daily for last 3 months was 1.2M.
-
What is the market cap of CAPR currently?
-
The market value of CAPR currently stands at $945.43M with its latest stock price at $20.68